The use of *Andrographis paniculata* and its effects on liver biochemistry of patients with gastrointestinal problems in Thailand during the COVID-19 pandemic: a cross-sectional study

Apichat Kaewdech¹, Siwanon Nawalerspanya¹,², Suraphon Assawasuwannakit¹,³, Naichaya Chamroonkul³, Sawangpong Jandee¹ & Pimsiri Sripongpun¹*

In the COVID-19 pandemic, healthcare facility supply and access are limited. There was an announcement promoting *Andrographis paniculata* (ADG) use for treatment of mild COVID-19 patients in Thailand, but misconception of taking for prevention might occur. Moreover, the effect of ADG on liver function test (LFT) has not been established. To study the ADG use and effect on LFT in patients with gastrointestinal (GI) problems, conducted a cross-sectional study including GI patients who voluntarily filled the ADG questionnaire in Aug–Sep 2021. LFT data at that visit and at the prior visit (if available) were obtained. The changes in LFT within the same person were analyzed and compared between patients with and without ADG consumption. During the study period, a total of 810 patients completed the survey, 168 patients (20.7%) took ADG within the past month. LFT data were available in 485 (59.9%) patients, the median alanine aminotransferase (ALT) change compared with the prior visit was higher in the ADG vs control group (+2 vs 0, p = 0.029), and 44.5% had increased ALT (>3 U/L) vs 32.2% in the ADG and control group, respectively (p = 0.018). Factors independently associated with an increased ALT, from a multivariable logistic regression, were ADG exposure (adjusted OR 1.62, p = 0.042), and patients with NAFLD who gained weight (adjusted OR 2.37, p = 0.046). In conclusion, one-fifth of GI patients recently took ADG, even it is not recommended for COVID-19 prevention. Those who took ADG are more likely to experience an increased ALT than who did not. The potential risk of ADG consumption on liver function should be further assessed.

The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the current global pandemic, affecting the economy, social lifestyle, and people's health, and resulting in significant morbidity and mortality. As the pandemic continues and some new variants are associated with a rapid widespread of the disease, the healthcare system is greatly affected. In many countries, not only healthcare facilities but also medications to treat COVID-19 were in short supply. As a result, considerable attempts are being made to find novel treatment modalities, including herbal medicine, in addition to vaccination. *Andrographis paniculata* (ADG) or known as "King of bitters", which has a major phytochemical constituent as Andrographolide, is a widely used ancient herbaceous plant that proposed to have various pharmacological effects including anti-pyretic, anti-inflammatory, analgesic or even hepatoprotectant. ADG has many local names according to different areas of the world, e.g., "Kalmegh" in India, "Chuan-Xin-Lian" in China, "Senshinren" in Japan, "Green chiretta" in Scandinavian countries, or "Fah Talai Jone" in Thailand. Recently, there have been published studies, both in vitro and in vivo, confirmed an anti-SARS-CoV-2 activity of ADG via a main
mechanism of viral main protease binding site inhibitor. In brief, ADG can potentially inhibit viral replication, improve patient's symptoms, reduce disease duration and severity in patients who exhibited mild symptoms of COVID-19; nonetheless, ADG had no effect on viral entry process or prevention of SARS-CoV-2 infection\(^7\)–\(^{11}\). The frequently reported side effects of ADG included nausea and vomiting, epigastric pain, diarrhea, chest pain, rash, and angioedema. Anaphylaxis or anaphylactic shock had been reported, there also were some reports regarding abnormal liver tests notably aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) elevation in some patients, but the data is scarce\(^{10,12–16}\). Surprisingly, although ADG has been used for a long time in Thailand, the COVID-19 situation was quite severe, like in many countries and causing antiviral medications shortage. With the anti-SARS-CoV-2 activity of ADG mentioned earlier, there was an announcement promoting ADG use to treat patients with confirmed SARS-CoV-2 infection who have mild symptoms of disease in Thailand. However, misconception of using ADG, not only for the treatment but also prevention of COVID-19, might occur on a public level, and it could lead to ADG misuse among healthy (non-SARS-CoV-2 infected) individuals. Moreover, it has been known that patients with pre-existing liver diseases, especially non-alcoholic fatty liver disease (NAFLD), might be at a higher risk to develop drug induced liver injury (DILI)\(^{17–19}\). Therefore, we conducted this study to evaluate the prevalence of ADG use among patients with gastrointestinal (GI) problems amid the pandemic of COVID-19 in Thailand and to determine the change in liver enzymes between those who had and did not have ADG consumption.

Materials and methods
We conducted a single center cross-sectional study at our institute, which is a tertiary care university hospital in Southern Thailand. The study protocol was approved by the Institutional Human Research Ethics Committee (HREC), Faculty of Medicine, Prince of Songkla University, Thailand (REC.64-370-14-1). All patients voluntarily provided informed consent before participating in the study. The study was conducted under the ethical guidelines of the 1975 Declaration of Helsinki.

Study population. We included all adult patients (age of at least 18 years old) with GI problems who visited the gastroenterology and hepatology outpatient clinic, and our endoscopic center between August and September 2021 (during the wave of delta variant of COVID-19 pandemic in Thailand) who voluntarily filled out the ADG questionnaire. Patients who had concurrent respiratory tract symptoms on the day of hospital visit and patients who reported to have other herbs or dietary supplements rather than ADG were excluded. In patients who had more than one visit during the study period, only the data from the first visit were included.

Patient recruitment. All patients who visited the GI clinic, and the endoscopic center during the study period were invited to join the study. The ADG questionnaire (detailed as shown below) was distributed to all those who were invited along with the informed consent. The patients were allowed to take their time to decide whether they wanted to participate in the study. Those who voluntarily participated in the study signed the informed consent and filled the ADG questionnaire by themselves and handed it back to the nurses before entering the doctor’s room. Those who did not want to participate in the study brought the blank document back to the nursing staff, visited the doctor, and received their treatment as usual.

Data collection. The questionnaire about ADG use is a single page questionnaire inquires whether the patient had consumed any herbal or dietary supplements aiming for health benefit within the past 30 days, and if so, what was that herbal or dietary supplement(s). In patients who reported having ADG within the past month, whether the product had been approved by Thai Food and Drug Administration (FDA), and how they consumed it (number of capsules or tablets per day and the duration of consumption) were inquired (the questionnaire in the original language is available in supplementary file 1). Other questions on the questionnaire included a history of self-SARS-CoV-2 infection, COVID-19 disease in family and close friends, how many shots of COVID-19 vaccination they had received at the time they filled out the questionnaire, their educational status, and monthly income.

Baseline demographic data of the patients i.e., age, sex, weight, height, underlying diseases, their GI conditions, and laboratory data including blood urea nitrogen (BUN), serum creatinine (Cr), and LFTs data regarding AST, ALT, alkaline phosphatase (ALP) at that visit and the prior visit (if available) were obtained from the hospital information system (HIS).

Determine the change in liver enzymes. In order to evaluate the change in LFTs in patients who had ADG consumption compared with who did not, we only obtained the laboratory data of the prior visit if it fulfilled the following criteria: the timing of the LFTs was at least 28 days but no longer than 1.5 years prior to the current visit.

And for the analysis regarding changes in liver enzymes, the patients with known cause(s) of abnormal LFTs at the current or prior visit (according to their primary doctor’s note in medical records) e.g., hepatocellular carcinoma progression, hepatobiliary or pancreatic tumor, flare of underlying viral hepatitis B or C, or active autoimmune liver diseases were excluded.

The change in AST and ALT were reported as a delta change in the same person (the level at the current visit minus level at the prior visit), and as a pattern of change: increase, stable, and decrease, respectively. Using the reference of upper limit of normal of ALT at 25 U/L and 35 U/L in women and men, respectively\(^20\), we used the margin of 10% change from normal value (±3 U/L from the prior visit) to be considered as a variation of ALT.
over time and categorized into the pattern ‘stable’. And those with delta ALT > 3 U/L and < 3 U/L were categorized into ‘increased’ and ‘decreased’ ALT groups, respectively.

**Statistical analysis.**  *Sample size calculation.* The sample size calculation was based on the sample size for a cohort study with binary outcome. As there was no previous study regarding ALT change in patients who had ADG and control, we hypothesized that 30% of the patients who took ADG would have an increased ALT compared with 14% in patients who did not, and the proportion of patients who had ADG would be around 20% of study participants. A total of at least 390 patients (65 in the ADG group and 325 in the control group) would be sufficient to demonstrate the result with a significance level of 0.05 and yield an 80% power.

**Data analysis.** All statistical analyses were performed using R program version 4.1.0 (Vienna, Austria). Descriptive statistics were used for baseline demographic data. Quantitative measurements were shown as mean ± SD or median with interquartile range (IQR) according to the distribution of observed values. The changes in laboratory data between the current visit and the prior visit within the same patients were analyzed using Wilcoxon signed-rank test. To compare between group of patients with and without ADG consumption, Chi-square test for categorical variables and Wilcoxon rank-sum test or t-test for continuous variables were used for the analyses. The univariable and multivariable logistic regression analyses were also carried out to identify independent factors associated with an increased in ALT level. A p-value of < 0.05 was considered statistically significant.

**Results**

**Baseline characteristics.** During the study period, 909 ADG questionnaires were filled, 23 were excluded as the questionnaires were filled by the same patients as they had frequent follow-up visits. Another 76 patients who reported to have herbal medications or dietary supplements other than ADG were also excluded. A total of 810 patients were included in this study. Of those, 168 patients (20.7%) had taken ADG within the past month. The baseline demographics, clinical characteristics, underlying co-morbidities as well as BMI changes appeared to be numerically higher, although not statistically significant, in patients with and without ADG consumption (ADG group VS control group) were comparable, except for higher proportion of male sex and a lower proportion of pre-existing liver cirrhosis were found in the ADG group than in the control group as shown in Table 1. When compared to the control group, patients in the ADG group had a significantly greater prevalence of having a history of SARS-CoV-2 infection either themselves (11% vs 6%) or in their close contacts (5.4% vs 1.9%).

Among patients who took ADG, 115 out of 168 (68.5%) of them reported to have Thai FDA-approved ADG products, while 31.5% reported that they take either non-Thai FDA-approved or did not know the Thai FDA approval status of the ADG products they had taken.

**Change in ALT in patients with and without ADG consumption.** Of all 810 patients, 514 (63.5%) had available ALT data at two timepoints (current and prior visits) to compare. Twenty-nine patients who had available LFTs data to compare, around one-third of them had NAFLD at baseline, these proportions were similar in both groups.

There were significantly differences in the changes in AST and ALT between the two groups, patients in the ADG group had a median ALT change of +2 (IQR: −3.8) vs 0 (IQR: −5.5) in the control group (p = 0.029). The same trend was also observed on the AST level (Table 2). And when categorized into the pattern of ALT change, a higher proportion of patients (44.5%) with ADG consumption experienced an ALT elevation > 3 U/L (increased ALT group) compared with 32.3% in patients with no ADG consumption (p = 0.018). Weight and body mass index (BMI) changes appeared to be numerically higher, although not statistically significant, in patients with ADG consumption as well.

We were also interested in the relationship between the dosage and duration of ADG consumption and ALT changes; however, ADG products in Thailand were available in a wide range of andrographolide dosages per product unit and forms (e.g., capsule, tablet, powder, or even fresh leaves). As a result, it was not possible to convert the patient-reported comprehensive ADG intake data into a standardized unit or to determine if the dosage and duration of ADG consumption were related to changes in ALT.

In both groups of patients, we looked at the impact of baseline NAFLD status on ALT elevation. According to the initial NAFLD status of the patients, Fig. 1 showed the difference in ALT levels between those who consumed ADG and those who did not. In patients without NAFLD at baseline (Fig. 1A), the ΔALT was similar in the ADG (median 0, IQR: −4.5 U/L) and control groups (median +1, IQR: −3.6 U/L, p = 0.276). The ΔALT did, however, seem to be greater in patients who took ADG (median +5, IQR: −4.14 U/L) than in those who did not (median 0, IQR: −7.7 U/L, p = 0.057) in those who had NAFLD at baseline (Fig. 1B).

**Factors associated with having an increased ALT.** As mentioned earlier, a higher percentage of patients in the ADG group had elevated ALT levels (ALT > 3 U/L), but the ADG group also showed a greater increase in BMI than the control group. A multivariable logistic regression analysis was then used to determine whether ADG consumption was independently associated with increased ALT. When adjusted for age, sex, and the interaction between NAFLD status and BMI change, ADG was still independently associated with the
development of ALT increased > 3 U/L with an adjusted odds ratio (OR) of 1.62 (95%CI 1.02–2.57, p = 0.042). While having NAFLD or having an increased BMI alone was not associated with an increased ALT, the interaction between having NAFLD and BMI was, with patients with NAFLD who had an increased BMI being more likely to have an increased ALT with an adjusted OR of 2.37 (95%CI 1.01–5.54, p = 0.046). The crude OR from univariable logistic regression analyses and the adjusted OR from a multivariable analysis are shown in Table 3.

We also looked into whether having a history of COVID-19 was linked to a higher ALT because those who took ADG had higher rates of SARS-CoV-2 infection themselves. However, a univariable logistic regression found no evidence of a significant association between a history of COVID-19 infection and an elevated ALT (crude OR 1.55, 95%CI 0.78–3.07, p = 0.217).

Discussion

In this study, we found that 20.7% of Thai patients had recently taken ADG during the COVID-19 pandemic aiming for their health benefit, but almost 90% of those who took ADG were not indicated as they did not have COVID-19. In the patients with available ALT data, we found that the patients in the ADG group had a significant increase in ALT compared to the patients in the control group (median ± 2 (IQR: −3,8) vs 0 (IQR: −5,5), p = 0.029, respectively). And when using the threshold of ALT increased more than 10% of ULN (ALT change > 3 U/L) for the definition of ALT elevation, ADG use and patients with NAFLD who gained weight were independently associated with having ALT elevation with an adjusted OR of 1.62 (95%CI 1.02–2.57, p = 0.042) and 2.37 (95%CI 1.01–5.54, p = 0.046), respectively.

Under the current circumstance of COVID-19 pandemic which affects people globally and disrupts the public health systems in many countries, there are shortages in both healthcare facilities and modern antiviral medications, hence, an attention towards herbal medicine is increasing. The prevalence of herbal medicine use during COVID-19 situation varied across the different areas of the world, for examples, 25.8% from study in India23, 42% in Nepal24, and 57.6% in Bangladesh25. A public survey in Hong Kong showed 19.3% prevalence of Chinese herbal medicine used26. While a cross-sectional survey in Peru found a high prevalence of medicinal plants use

| Table 1. Baseline clinical characteristics between control group and ADG group in all 810 patients. ADG, andrographolide; ASA, aspirin; BMI, body mass index; CAD/CVD, coronary artery disease/cardiovascular disease; COVID-19, Coronavirus disease 2019; DM, diabetes mellitus; GERD, gastroesophageal reflux disease; GI, gastrointestinal; IBS, irritable bowel syndrome; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HTN, hypertension; IQR, interquartile range; N, number of patients; NAFLD, non-alcoholic fatty liver disease; Ph.D., Doctor of Philosophy. |
| Variables | No ADG (n = 642) | ADG (n = 168) | P value |
| Age: median (IQR), years | 59 (49.2,68) | 56.5 (48.2,65.8) | 0.138 |
| Sex: male, N (%) | 321 (50.1) | 99 (59.3) | 0.034 |
| BMI: median (IQR), kg/m² | 24.1 (21.7,26.8) | 24.1 (21.8,27.4) | 0.824 |
| Underlying comorbidities: N (%) | | | |
| DM | 136 (44.7) | 26 (41.3) | 0.614 |
| HTN | 171 (56.2) | 36 (57.1) | 0.897 |
| CAD/CVD, on ASA | 58 (19.1) | 14 (22.2) | 0.567 |
| GI/liver conditions: N (%) | | | |
| Dyspepsia/GERD/IBS/constipation | 107 (17.6) | 38 (23.6) | 0.083 |
| Hepatitis | 350 (57.6) | 96 (59.6) | 0.637 |
| Cirrhosis | 193 (31.7) | 29 (18) | <0.001 |
| HCC | 72 (11.8) | 13 (8.1) | 0.175 |
| Cause of liver diseases it they had hepatitis, cirrhosis, or HCC: N (%) | | | |
| HBV | 183 (45.9) | 55 (54.5) | 0.123 |
| HCV | 48 (12) | 7 (6.9) | 0.143 |
| NAFLD | 151 (37.8) | 44 (43.6) | 0.292 |
| Alcohol | 36 (9) | 10 (9.9) | 0.785 |
| COVID-19 related history: N (%) | | | |
| Self-reported infected with COVID-19 | 38 (6) | 18 (11) | 0.026 |
| Hx of COVID-19 in family or close friends | 12 (1.9) | 9 (5.4) | 0.024 |
| History of COVID-19 vaccination (≥1 shot) | 496 (77.6) | 131 (78) | 0.922 |
| Other demographic data: N (%) | | | |
| Education level | | | 0.722 |
| - Elementary school | 165 (26.8) | 39 (24.8) | |
| - High school | 149 (24.2) | 36 (22.9) | |
| - College/Bachelor's degree | 235 (38.1) | 60 (38.2) | |
| - Master's degree or Ph.D | 67 (10.9) | 22 (14) | |
| Income per month, median (IQR) Thai Baht | 20,000 (10,000, 35,000) | 24,500 (10,000, 40,000) | 0.383 |
Table 2. Comparison between control group VS ADG group in patients with available laboratory data (N = 486). ADG, andrographolide; ALP, Alkaline phosphatase; ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; BMI, body mass index; BUN, blood urea nitrogen; IQR, interquartile range; N, number of patients; NAFLD, non-alcoholic fatty liver disease.

| Variables | No ADG (n = 375) | ADG (n = 110) | P value |
|-----------|------------------|---------------|---------|
| Presence of NAFLD at baseline: N (%) | 125 (33.3) | 35 (31.8) | 0.766 |
| Weight change: median (IQR), kg | 0 (−1.1) | 0.4 (−1.3) | 0.100 |
| BMI change: median (IQR), kg/m² | 0 (−0.4,0.4) | 0.2 (−0.4,0.5) | 0.086 |

At the current visit

| Variables | No ADG (n = 375) | ADG (n = 110) | P value |
|-----------|------------------|---------------|---------|
| BUN, median (IQR) mg/dL | 12.4 (9.8,15.6) | 11.9 (10,14) | 0.290 |
| Creatinine, median (IQR) mg/dL | 0.9 (0.7,1.1) | 0.9 (0.7,1) | 0.255 |
| AST, median (IQR) U/L | 29 (23,39) | 28 (23,37) | 0.383 |
| ALT, median (IQR) U/L | 27 (19,39) | 27.5 (19,39.8) | 0.782 |
| ALP, median (IQR) U/L | 82 (67,107) | 73 (60,92) | 0.005 |

At the prior visit

| Variables | No ADG (n = 375) | ADG (n = 110) | P value |
|-----------|------------------|---------------|---------|
| BUN, median (IQR) mg/dL | 12.6 (10,2,16.3) | 12.1 (10,11,14.8) | 0.322 |
| Creatinine, median (IQR) mg/dL | 0.8 (0.7,1) | 0.9 (0.7,1) | 0.308 |
| AST, median (IQR) U/L | 28 (22,37) | 26 (21,38) | 0.136 |
| ALT, median (IQR) U/L | 27 (19,39) | 23 (18,2,34.5) | 0.360 |
| ALP, median (IQR) U/L | 81.5 (65,102) | 68 (58,2,89.5) | 0.001 |

Change (Δ) in the same patient (level at current–prior visit)

| Variables | No ADG (n = 375) | ADG (n = 110) | P value |
|-----------|------------------|---------------|---------|
| Creatinine, median (IQR) mg/dL | 0 (0,0,1) | 0 (0,0) | 0.350 |
| AST, median (IQR) U/L | 0 (−5,5) | 2 (−3,8) | 0.028 |
| ALT, median (IQR) U/L | 0 (−5,5) | 2 (−3,8) | 0.029 |
| ALP, median (IQR) U/L | 1 (−5,8) | 1 (−5.6,5) | 0.812 |

ALT change group

| | No ADG (n = 375) | ADG (n = 110) | P value |
|-----------|------------------|---------------|---------|
| - Increase ALT level | 121 (32.3) | 49 (44.5) | 0.049 |
| - Stable ALT level | 146 (38.9) | 38 (34.5) | 0.360 |
| - Decrease ALT level | 108 (28.8) | 23 (20.9) | 0.018 |

- ALT increase > 3 U/L, yes, N (%) | 121 (32.2) | 49 (44.5) | 0.018 |

Figure 1. Violin plot of alanine aminotransferase (ALT) changes between Andrographis paniculata (ADG) VS control group stratified by non-alcoholic fatty liver disease (NAFLD) status. (A) Patients without NAFLD, and (B) Patients with NAFLD.
Additional, a recent multicenter randomized controlled trial in China including 130 patients also showed that 10.8% of patients in ADG group had increased ALT levels, and 13.8% had hyperbilirubinemia, compared to 10.8% and 7.7% in the control group, respectively.10. Despite the fact that doing so was not advised. And those with ADG had significantly higher AST and ALT levels than those without ADG; a median ALT change of +2 (IQR: −5,5) in patients with ADG vs 0 (IQR: −3,8) in patients with ADG (p = 0.029), and a median AST change of +2 (IQR: −3,8) in patients with ADG vs 0 (IQR: −5,5) in patients without ADG (p = 0.028).

The mechanism of ADG use and ALT elevation is yet to be discovered. In the present study, andrographolide can be in the form of compound, extract, or even traditional preparations. Formulations other than the pure compound itself will have different andrographolide and phytoconstituent content. The complex and rich nature of phytoconstituents, which varies with preparation methods/formulation in herbal medicine might lead to different pharmacological effects including toxicity. Moreover, the dosage, duration of consumption, or preparation forms of ADG might be associated with ALT change in ADG users. Due to a variety of amount, durations, and

| Factors                  | Univariable analysis | Multivariable analysis |
|--------------------------|----------------------|------------------------|
| Age, every 1-year increase | 0.98 (0.96,0.99)     | 0.98 (0.96,0.99)       | 0.003 |
| Sex, female vs male      | 0.74 (0.51,1.1)      | 0.77 (0.52,1.15)       | 0.198 |
| ADG use, yes vs no       | 1.83 (1.17,2.85)     | 1.62 (1.02,2.57)       | 0.042 |
| Presence of NAFLD, yes vs no | 1.22 (0.81,1.82)   | 0.84 (0.48,1.46)       | 0.528 |
| BMI increased, yes vs no | 1.33 (0.9,1.96)      | 0.9 (0.55,1.48)        | 0.678 |
| Presence of NAFLD and BMI increased, yes vs no | – | 2.37 (1.01,5.54) | 0.046 |

Table 3. Logistic regression analyses of predicting factors associated with an increased ALT (ΔALT > 3 U/L). ADG, andrographolide; ALT, Alanine aminotransferase; BMI, body mass index; NAFLD, non-alcoholic fatty liver disease; OR, odd ratio.
preparations of ADG use in our study, and there is no standardized protocol to calculate the andrographolide amount from a wide range of different ADG products in Thailand, a subsequent analysis regarding this issue cannot be made. Further studies are needed for a better clarification of the association between ADG and ALT change.

Additionally, as shown in Fig. 1, an increase in ALT in ADG users was more noticeable in patients with NAFLD than in patients without NAFLD, supporting previous research that NAFLD patients may be at risk of developing DILI. Nonetheless, we also concerned that ALT elevation in our patients could be from various conditions, therefore, we had excluded patients with known cause of ALT elevation such as tumor progression or flare of viral or autoimmune hepatitis, and patients reported to have other herbal or dietary supplements rather than ADG prior to the analyses of ALT change. In addition, during the COVID-19 pandemic, weight gain may be encountered in many patients33, and it might link to fatty liver and ALT elevation in a sequela. Taking this issue into consideration, we performed a multivariable logistic regression analysis of factors associated with the development of an increased in ALT (>3 U/L), after an adjustment with age, sex, baseline NAFLD status, and whether the patients had an increased BMI, ADG use was still independently associated with ALT elevation with an adjusted OR of 1.62 (95%CI 1.02–2.57, p = 0.042).

Interestingly, neither having NAFLD status nor an increase in BMI alone was associated with an ALT elevation, but only patients with NAFLD who had BMI increased were independently associated with an increased risk of having ALT elevation for an adjusted OR of 2.37 (95%CI 1.01–5.54, p = 0.046).

The present study, to the best of our knowledge, included the largest number of patients comparing changes in ALT level between ADG and non-ADG users to date. The results of our study highlighted the association between the ADG usage and ALT elevation, an also demonstrated the significance of baseline NAFLD and weight gain in ALT elevation in this setting.

We acknowledged some limitations of our study, the causality of ADG causing DILI cannot be firmly concluded as the design of the study is rather cross-sectional and retrospective, and as mentioned earlier, there were different preparations, duration, and dosing of ADG used in our study making it impossible to identify whether Andrographolide compound itself or some ingredients from the different preparations of ADG that caused ALT elevation. And we did not record all medications the patients had taken regularly, as there might be some herb-drug interaction, or the use of other drugs may potentiate liver injury, however, we had excluded the effects of other herbal/dietary supplements on the results of this study as 76 patients who reported to have herbal medications or dietary supplements other than ADG were not included in the LFTs analysis. Lastly, the interval between the first and second LFTs test among ADG and non-ADG users were varied and follow up LFTs after stopped ADG in patients who had ALT elevation were not performed, as well as rechallenge.

In summary, we found that at least one-fifth of the Thai patients taking ADG during the COVID-19 pandemic, in which most of them were misused. Patients with ADG consumption experienced more ALT elevation than in those without ADG, and patients with NAFLD who had gained weight were independently associated with an increased ALT >3 U/L compared to baseline. The potential risk of ADG consumption on liver function should be further assessed in future studies with adequate documentation of detailed quality-related information on ADG preparations, to better establish a causal-relationship as well as the need for public precaution.

Data availability
The datasets generated and/or analyzed during the current study are not publicly available due to personal health information privacy policy but deidentification data are available from the corresponding author on reasonable request.

Received: 29 April 2022; Accepted: 26 October 2022
Published online: 29 October 2022

References
1. Ağagündüz, D., Çelik, M., Çıtar-Dazıroğlu, M. & Capasso, R. Emergent drug and nutrition interactions in COVID-19: A comprehensive narrative review. Nutrients 13(5), 1550 (2021).
2. Tallei, T. E. et al. A comprehensive review of the potential use of green tea polyphenols in the management of COVID-19. Evid.-Based Complement. Altern. Med. 2021, 1–13 (2021).
3. Dai, Y. et al. Overview of pharmacological activities of Andrographis paniculata and its major compound andrographolide. Crit. Rev. Food Sci. Nutr. 59(sup1), S17–S29 (2019).
4. Chao, W. W. & Lin, B. F. Hepatoprotective diterpenoids isolated from Andrographis paniculata. Chin. Med. 3(3), 136–143 (2012).
5. Chua, L. S. Review on liver inflammation and antiinflammatory activity of Andrographis paniculata for hepatoprotection. Phytother. Res. 28(11), 1589–1598 (2014).
6. Kumar, R. A., Sridevi, K., Kumar, N. V., Nanduri, S. & Rajagopal, S. Anticancer and immunomodulatory compounds from Andrographis paniculata. J. Ethnopharmacol. 192(2–3), 291–295 (2020).
7. Sa-Ngamsunton, K. et al. Anti-SARS-CoV-2 activity of andrographis paniculata extract and its major component andrographolide in human lung epithelial cells and cytotoxicity evaluation in major organ cell representatives. J. Nat. Prod. 84(4), 1261–1270 (2021).
8. Ermozghi, S. K., Raja, K., Sebastine, I. & Joseph, J. Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: An in silico approach. J. Biomol. Struct. Dyn. 39(9), 3092–3098 (2021).
9. Shi, T. H. et al. Andrographolide and its fluorescent derivative inhibit the main proteases of 2019-nCoV and SARS-CoV through covalent linkage. Biochem. Biophys. Res. Commun. 533(3), 467–473 (2020).
10. Zhang, X. Y. et al. Efficacy and safety of Xiyanping injection in the treatment of COVID-19: A multicenter, prospective, open-label and randomized controlled trial. Phytother. Res. 35(8), 4401–4410 (2021).
11. Ervina, M., Fadhil Pratama, M. R., Poerwono, H. & Siswodihardjo, S. The coronavirus disease 2019 main protease inhibitor from Andrographis paniculata (Burm. f) Ness. J. Adv. Pharm. Technol. Res. 11(4), 157–162 (2020).
12. Pokhagul, P. & Kulsumboon, W. Signal detection of blood glucose lowering drugs and herbal medicines in the Thai databases on adverse drug events (Thai Vigibase). Thai J. Pharm. Pract. 11(2), 333–341 (2019).
supervision. Acquisition and interpretation. S.N. is responsible for drafting the manuscript. All authors contributed to critical analysis, interpretation of the data, and critical revision of the manuscript. S.N., S.A., A.K. are responsible for data collection.

This study was funded by the Gastroenterological Association of Thailand.

Acknowledgements
This work was supported from the Faculty of Medicine, Prince of Songkla University, Thailand and the Gastroenterological Association of Thailand.

Author contributions
Guarantor of the article: P.S. P.S. made a substantial contribution to the study’s concept and design, data analysis, interpretation of the data, and critical revision of the manuscript. S.N., S.A., A.K. are responsible for data acquisition and interpretation. S.N. is responsible for drafting the manuscript. All authors contributed to critical revisions and approved the final manuscript. P.S., S.J., and N.C. are senior authors who are responsible for study supervision.

Funding
This study was funded by the Gastroenterological Association of Thailand.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-23189-7.

Correspondence and requests for materials should be addressed to P.S.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
